Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Stock Information for Syros Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Syros Pharmaceuticals Inc.

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Syros to Participate in TD Cowen 44th Annual Health Care Conference
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.